Factors associated with mucosal healing in patients with ulcerative colitis in clinical remission

Inflammatory Bowel Diseases

Volumn 21, Issue 4, 2015, Pages 840-846

  Shi, Hai Yun ^a   Chan, Francis K L ^a   Tsang, Steven W C ^b   Hui, Yee Tak ^c   Sze, Shun Fung ^c   Ching, Jessica Y L ^a   Chung, Tiffany ^a   Iu, Catherine Y Y ^d   Lo, Fu Hang ^e   Shan, Edwin H S ^f   Li, Michael K K ^g   Wu, Justin C Y ^a   Sung, Joseph J Y ^a   Ng, Siew C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b TSEUNG KWAN O HOSPITAL   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^f Caritas Medical Centre Hong Kong   (Hong Kong)

^g TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

duration of clinical remission; immunosuppressant; mucosal healing; severity of mucosal inflammation; ulcerative colitis

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ADULT; ARTICLE; COLONOSCOPY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; ULCER HEALING; ULCERATIVE COLITIS; ADOLESCENT; AGED; COLITIS, ULCERATIVE; INTESTINE MUCOSA; PATHOLOGY; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; COLONOSCOPY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTESTINAL MUCOSA; LOGISTIC MODELS; MALE; MIDDLE AGED; REMISSION, SPONTANEOUS;

EID: 84925384386     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000334     Document Type: Article

References (51)

1. Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases. A systematic review. Gut. 2012;61:1619-1635.
2. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990.
3. Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine. A prospective, multicenter study. Inflamm Bowel Dis. 2012;18:1006-1010.
4. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194-1201.
5. Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422.
6. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9: 483-489.e483.
7. Laharie D, Filippi J, Roblin X, et al. Impact of mucosal healing on longterm outcomes in ulcerative colitis treated with infliximab. A multicenter experience. Aliment Pharmacol Ther. 2013;37:998-1004.
8. Actis G, Pellicano R, David E, et al. Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer. A clinicalpractice-based forecast. Inflamm Allergy Drug Targets. 2010;9:6-9.
9. Baars JE, Nuij VJAA, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012;18:1634-1640.
10. Rosenberg L, Lawlor GO, Zenlea T, et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013;19:779-784.
11. Brahmania M, Bernstein C. Physician global assessments or blood tests do not predict mucosal disease activity in ulcerative colitis. Can J Gastroenterol Hepatol. 2014;28:325-329.
12. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
13. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332-341.
14. Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013;19:1034-1042.
15. Nancey S, Boschetti G, Moussata D, et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2013;19:1043-1052.
16. Guardiola J, Lobaton T, Rodriguez-Alonso L, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014; 12:1865-1870.
17. Dick A, Holt L, Dalton E. Persistence of mucosal abnormality in ulcerative colitis. Gut. 1966;7:355-360.
18. Swaminath A. Use of methotrexate in inflammatory bowel disease in 2014. A user's guide. World J Gastrointest Pharmacol Ther. 2014;5:113-121.
19. Yoon JY, Park SJ, Hong SP, et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014;59:829-837.
20. Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis. Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851-1858.
21. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin. A predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017-1020.
22. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-169.
23. Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal Immunochemical test. Am J Gastroenterol. 2012;108:83-89.
24. Bewtra M, Brensinger CM, Tomov VT, et al. An optimized patientreported ulcerative colitis disease activity measure derived from the mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis. 2014;20:1070-1078.
25. Gibson PR, Vaizey C, Black CM, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia. A cross-sectional, observational study. J Crohns Colitis. 2014;8:598-606.
26. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10: CD000544.
27. Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;9:CD000478.
28. Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126-137.
29. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660-671.
30. Bickston SJ, Behm BW, Tsoulis DJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;8:CD007571.
31. Thorlund K, Druyts E, Mills EJ, et al. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients na?ve to anti-TNF therapy. An indirect treatment comparison meta-analysis. J Crohns Colitis. 2014;8:571-581.
32. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis a systematic review and network meta-analysis. Ann Intern Med. 2014;160:704-711.
33. Kawalec P, Mikrut A, qopuch S. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis. J Gastroenterol Hepatol. 2014;29:1159-1170.
34. Cominelli F, Lv R, Qiao W, et al. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy. A meta-analysis. PLoS One. 2014;9: e86692.
35. Ardizzone S. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.
36. Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis. A double-blind, doubledummy, randomised, non-inferiority trial. Gut. 2008;58:233-240.
37. Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011;33:672-678.
38. Römkens TEH, Kampschreur MT, Drenth JPH, et al. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a metaanalysis of clinical trials. Inflamm Bowel Dis. 2012;18:2190-2198.
39. Bouguen G, Levesque BG, Pola S, et al. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014;20:231-239.
40. Danese S, Colombel JF, Peyrin-Biroulet L, et al. Review article: the role of anti-TNF in the management of ulcerative colitis-past, present and future. Aliment Pharmacol Ther. 2013;37:855-866.
41. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. Gastroenterology. 2013;145:158-165.e152.
42. Prideaux L, Kamm MA, De Cruz PP, et al. Inflammatory bowel disease in Asia. A systematic review. J Gastroenterol Hepatol. 2012;27:1266-1280.
43. Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China. A prospective population-based study. J Gastroenterol Hepatol. 2013;28:1148-1153.
44. Yang H, Li Y, Wu W, et al. The incidence of inflammatory bowel disease in Northern China. A prospective population-based study. PLoS One. 2014;9:e101296.
45. Langhorst J, Hofstetter A, Wolfe F, et al. Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis. A prospective 12-month follow-up study. Inflamm Bowel Dis. 2013;19:2380-2386.
46. Farkas K, Lakatos PL, Szucs M, et al. Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy. World J Gastroenterol. 2014;20: 2995-3001.
47. Oliva S, Di Nardo G, Hassan C, et al. Second-generation colon capsule endoscopy vs. colonoscopy in pediatric ulcerative colitis. A pilot study. Endoscopy. 2014;46:485-492.
48. Meister T, Heinzow HS, Domagk D, et al. Colon capsule endoscopy versus standard colonoscopy in assessing disease activity of ulcerative colitis. A prospective trial. Tech Coloproctol. 2013;17:641-646.
49. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894-1898.
50. Travis SPL, Schnell D, Krzeski P, et al. Reliability and Initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987-995.
51. Osada T, Ohkusa T, Yokoyama T, et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: Inter-and intraobserver consistency. Inflamm Bowel Dis. 2010;16:192-197.